New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
13:32 EDTAMGNAmgen finalizes $762M agreement to settle federal investigations
Amgen announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations. Amgen will pay approximately $612M to resolve its civil liability related to certain promotional practices related to the drugs Aranesp, EPOGEN, NEUPOGEN, Neulasta, Enbrel and Sensipar as alleged in the unsealed qui tam complaints and $150M to resolve its criminal liability relating to the marketing of Aranesp, and the $762M agreement is covered by a 3Q11 charge. The company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. As part of the agreement, Amgen has pleaded guilty to a single misdemeanor count of misbranding Aranesp by promoting it in a way that was different from the dosages in the label. The plea was entered yesterday in the U.S. District Court for the Eastern District of New York and was accepted today by the same court.
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
16:04 EDTAMGNAmgen to present present several studies related to brodalumab, Enbrel, ABP 501
Subscribe for More Information
07:39 EDTAMGNAmgen reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 30, 2014
07:30 EDTAMGNSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
07:26 EDTAMGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
September 22, 2014
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
September 17, 2014
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use